Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to ...

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to ...

Among patients with COPD and type 2 inflammation, investigator-reported emphysema did not change benefits seen with dupilumab ...

Remote interventions reduced hospital readmissions by over 50% in COPD patients, highlighting their potential to disrupt frequent exacerbation cycles. Significant improvements in quality of life were ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to a new study. The study ...

Patients with acute COPD exacerbation should be treated with systemic corticosteroids, antibiotics and NPPV. Systemic corticosteroids reduce treatment failures in both in-hospital and outpatient ...

Perspective from Vijay Sam Nethala, MD The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, COPD exacerbation history groups were “mediocre” in estimating moderate and severe ...

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical ...

The primary end point was the annualized rate of moderate or severe COPD exacerbations. An exacerbation was considered to be moderate if it resulted in treatment with systemic glucocorticoids ...

which demonstrated a significant minimisation in the annualised rate of moderate/severe exacerbation rates among patients. Nucala targets interleukin-5 (IL-5), a cytokine involved in type 2 ...